Skip to main content

Advertisement

Table 1 Eighteen-month changes with docosahexaenoic acid or placebo treatment by apolipoprotein E ε4 status on CSF DHA, Aβ42, Tau and p-Tau levels

From: The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease

  DHA treated, APOE ɛ4 non-carriers (n = 4) Placebo treated, APOE ɛ4 non-carriers (n = 4) DHA treated, APOE ɛ4 carriers (n = 25) Placebo treated, APOE ɛ4 carriers (n = 11)
  Baseline 18 months Baseline 18 months Baseline 18 months Baseline 18 months
DHA,a % by weight 2.21 (0.44) 3.71 (0.71) 2.66 (0.81) 1.95 (0.28) 2.46 (0.59) 3.38 (0.90) 2.28 (0.6) 2.18 (0.50)
Aβ42, pg/ml 208 (55) 189 (51) 190 (36) 183 (36) 150 (30) 140 (30) 151 (35) 145 (33)
Tau, pg/ml 120 (110) 121 (125) 118 (42) 129 (35) 112 (53) 108 (136) 133 (94) 126 (88)
p-Tau,b pg/ml 39 (43) 40 (43) 47 (23) 53 (28) 47 (18) 44 (17) 53 (37) 51(33)
  1. Abbreviations: Aβ42 amyloid-β42, APOE apolipoprotein E, CSF cerebrospinal fluid, DHA docosahexaenoic acid, p-Tau phosphorylated Tau
  2. Data are presented as mean (SD). Two-way analysis of variance was used to compare placebo and treatment groups by genotype
  3. a p = 0.07 for an interaction between treatment arm and APOE genotype
  4. b p = 0.04 for the difference in p-Tau by APOE groups